Stock Analiz

Dare Bioscience, Inc. DARE

Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026

$0.66Market cap $13M
Open the interactive analysis →

Dare Bioscience, Inc. (DARE) is a healthcare company listed in the US with a market value of about $13M. In the twelve months to June 30, 2026 it had revenue of $1M and net income of -$11M, a net margin of -804.4%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -236%.

About Dare Bioscience

Dare Bioscience is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $80000 in 2014 to $1M in 2025, growth of about 26.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 59% over three years (dilution for shareholders). It spends 536% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S9.5
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-90.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)10429.4%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-11028.8%
ROIC (5-yr avg.)-236.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1M$1M$9784$3M$10M$0————$766000
Net income-$11M-$13M-$4M-$30M-$31M-$39M-$27M-$14M-$17M-$12M-$672687
Free cash flow-$12M-$10M$5M-$39M-$18M-$29M-$25M-$13M-$10M-$3M-$907299
EPS (diluted)$-0.71$-1.20$-0.48$-4.15$-4.44$-7.56$-10.92$-11.64$-18.84$42.72$-9.72
Net margin-804.4%-1300.7%-41430.9%-1074.2%-309.5%—————-87.8%
ROIC—-338.4%——-270.5%-100.1%—-1156.1%-187.4%-84.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $6.33, 863% above the current price; targets range from $2.00 to $12.00; the consensus rating is “none”; expected EPS is $-0.73 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Dare Bioscience pay a dividend?

Not currently.

Is Dare Bioscience a good stock to buy?

We do not give buy or sell advice. Dare Bioscience scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.